Maha Reda Farhat, M.D., M.D.,C.M.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mycobacterium tuberculosis | 38 | 2024 | 1914 | 8.830 |
Why?
|
Tuberculosis, Multidrug-Resistant | 20 | 2024 | 934 | 6.360 |
Why?
|
Tuberculosis | 22 | 2024 | 2015 | 3.920 |
Why?
|
Antitubercular Agents | 25 | 2024 | 1374 | 3.840 |
Why?
|
Microbial Sensitivity Tests | 20 | 2024 | 1936 | 2.180 |
Why?
|
Drug Resistance, Bacterial | 9 | 2024 | 1048 | 1.880 |
Why?
|
Genome, Bacterial | 11 | 2024 | 783 | 1.740 |
Why?
|
Rifampin | 5 | 2024 | 339 | 1.610 |
Why?
|
Fluoroquinolones | 3 | 2017 | 306 | 1.370 |
Why?
|
Phylogeny | 12 | 2024 | 2806 | 1.360 |
Why?
|
Drug Resistance, Multiple, Bacterial | 5 | 2021 | 585 | 1.260 |
Why?
|
Antibiotics, Antitubercular | 1 | 2022 | 99 | 0.750 |
Why?
|
Tuberculosis, Lymph Node | 1 | 2021 | 21 | 0.740 |
Why?
|
Nitroimidazoles | 1 | 2020 | 117 | 0.660 |
Why?
|
Rifabutin | 1 | 2019 | 59 | 0.650 |
Why?
|
Water Microbiology | 1 | 2019 | 113 | 0.610 |
Why?
|
Tuberculin Test | 3 | 2008 | 206 | 0.600 |
Why?
|
Tuberculosis, Pulmonary | 2 | 2022 | 831 | 0.590 |
Why?
|
Molecular Typing | 1 | 2017 | 116 | 0.560 |
Why?
|
Delayed Diagnosis | 1 | 2021 | 463 | 0.550 |
Why?
|
BCG Vaccine | 4 | 2022 | 369 | 0.520 |
Why?
|
Host-Pathogen Interactions | 1 | 2024 | 1454 | 0.510 |
Why?
|
Molecular Diagnostic Techniques | 3 | 2019 | 610 | 0.500 |
Why?
|
Polymorphism, Single Nucleotide | 7 | 2024 | 15908 | 0.500 |
Why?
|
DNA Gyrase | 1 | 2016 | 85 | 0.500 |
Why?
|
Mutation | 19 | 2024 | 30016 | 0.490 |
Why?
|
Drug Resistance, Microbial | 2 | 2018 | 825 | 0.480 |
Why?
|
Computational Biology | 4 | 2021 | 3509 | 0.480 |
Why?
|
Appendicitis | 1 | 2021 | 675 | 0.480 |
Why?
|
Clostridium Infections | 1 | 2021 | 557 | 0.470 |
Why?
|
Software | 5 | 2022 | 4431 | 0.470 |
Why?
|
Biofilms | 1 | 2019 | 626 | 0.460 |
Why?
|
Respiratory Muscles | 1 | 2013 | 142 | 0.410 |
Why?
|
Virulence | 4 | 2024 | 1299 | 0.410 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 1086 | 0.400 |
Why?
|
Genomics | 7 | 2024 | 5822 | 0.390 |
Why?
|
Adjuvants, Immunologic | 2 | 2007 | 990 | 0.380 |
Why?
|
Isoniazid | 3 | 2024 | 283 | 0.380 |
Why?
|
Clofazimine | 2 | 2021 | 41 | 0.370 |
Why?
|
Anti-Bacterial Agents | 6 | 2024 | 7402 | 0.360 |
Why?
|
Respiration Disorders | 1 | 2013 | 367 | 0.340 |
Why?
|
Bacterial Proteins | 5 | 2024 | 3842 | 0.320 |
Why?
|
Selection, Genetic | 1 | 2013 | 868 | 0.320 |
Why?
|
Humans | 58 | 2024 | 760617 | 0.320 |
Why?
|
Immunity, Innate | 1 | 2021 | 3045 | 0.310 |
Why?
|
Mass Screening | 1 | 2024 | 5424 | 0.310 |
Why?
|
Epistasis, Genetic | 2 | 2021 | 350 | 0.300 |
Why?
|
India | 3 | 2023 | 2286 | 0.300 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 1 | 2013 | 556 | 0.290 |
Why?
|
Sputum | 2 | 2021 | 506 | 0.290 |
Why?
|
Sequence Analysis, DNA | 4 | 2022 | 4739 | 0.290 |
Why?
|
Intensive Care Units | 2 | 2023 | 3742 | 0.270 |
Why?
|
Models, Statistical | 2 | 2019 | 5073 | 0.240 |
Why?
|
Respiratory Function Tests | 2 | 2024 | 1683 | 0.240 |
Why?
|
Ethambutol | 2 | 2022 | 59 | 0.240 |
Why?
|
Ethionamide | 1 | 2024 | 11 | 0.230 |
Why?
|
Genetic Predisposition to Disease | 3 | 2024 | 17878 | 0.230 |
Why?
|
Genome-Wide Association Study | 6 | 2024 | 12661 | 0.220 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2024 | 322 | 0.220 |
Why?
|
Databases, Genetic | 2 | 2021 | 1742 | 0.220 |
Why?
|
Genes, Bacterial | 2 | 2017 | 1073 | 0.220 |
Why?
|
Gene Expression Regulation, Bacterial | 2 | 2024 | 1131 | 0.200 |
Why?
|
ROC Curve | 2 | 2021 | 3575 | 0.200 |
Why?
|
Prisons | 1 | 2024 | 174 | 0.200 |
Why?
|
Mycobacterium bovis | 1 | 2022 | 146 | 0.200 |
Why?
|
Contact Tracing | 1 | 2024 | 270 | 0.200 |
Why?
|
Amikacin | 1 | 2021 | 47 | 0.200 |
Why?
|
Phylogeography | 1 | 2021 | 72 | 0.200 |
Why?
|
Evolution, Molecular | 2 | 2021 | 1880 | 0.190 |
Why?
|
Kanamycin | 1 | 2021 | 63 | 0.190 |
Why?
|
Prisoners | 1 | 2024 | 314 | 0.180 |
Why?
|
Incidence | 3 | 2024 | 21337 | 0.180 |
Why?
|
Reference Standards | 1 | 2024 | 1002 | 0.180 |
Why?
|
DNA Barcoding, Taxonomic | 1 | 2021 | 132 | 0.180 |
Why?
|
Stenotrophomonas maltophilia | 1 | 2020 | 18 | 0.180 |
Why?
|
Brazil | 1 | 2024 | 1228 | 0.170 |
Why?
|
Cholecystitis | 1 | 2020 | 180 | 0.170 |
Why?
|
Oxazoles | 1 | 2020 | 199 | 0.160 |
Why?
|
Cluster Analysis | 4 | 2020 | 2700 | 0.160 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2020 | 386 | 0.160 |
Why?
|
Community-Acquired Infections | 1 | 2023 | 469 | 0.160 |
Why?
|
Antigens, Bacterial | 1 | 2024 | 1141 | 0.160 |
Why?
|
Extensively Drug-Resistant Tuberculosis | 1 | 2019 | 85 | 0.150 |
Why?
|
Bacterial Typing Techniques | 1 | 2019 | 263 | 0.150 |
Why?
|
Drug Tolerance | 1 | 2020 | 367 | 0.150 |
Why?
|
DNA, Bacterial | 2 | 2022 | 1471 | 0.150 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2020 | 238 | 0.150 |
Why?
|
Private Sector | 1 | 2021 | 394 | 0.150 |
Why?
|
Reproducibility of Results | 4 | 2021 | 20074 | 0.150 |
Why?
|
Pancreas | 1 | 2024 | 1690 | 0.150 |
Why?
|
Retrospective Studies | 8 | 2023 | 80566 | 0.140 |
Why?
|
Genome, Viral | 1 | 2020 | 665 | 0.140 |
Why?
|
Hospital Mortality | 3 | 2023 | 5293 | 0.140 |
Why?
|
Genetic Loci | 3 | 2024 | 2624 | 0.130 |
Why?
|
Workflow | 1 | 2021 | 849 | 0.130 |
Why?
|
Adaptation, Physiological | 1 | 2023 | 1300 | 0.130 |
Why?
|
Insurance Claim Review | 1 | 2021 | 741 | 0.130 |
Why?
|
Female | 16 | 2024 | 392148 | 0.130 |
Why?
|
Neisseria gonorrhoeae | 1 | 2018 | 239 | 0.130 |
Why?
|
Peru | 1 | 2019 | 890 | 0.130 |
Why?
|
Genotype | 5 | 2024 | 12978 | 0.130 |
Why?
|
Bacteremia | 1 | 2023 | 977 | 0.130 |
Why?
|
Genetics, Population | 1 | 2021 | 935 | 0.130 |
Why?
|
Benchmarking | 1 | 2022 | 1045 | 0.130 |
Why?
|
Respiratory Insufficiency | 1 | 2024 | 1230 | 0.120 |
Why?
|
Gastrointestinal Diseases | 2 | 2021 | 1201 | 0.120 |
Why?
|
Metagenomics | 1 | 2019 | 463 | 0.120 |
Why?
|
Ofloxacin | 1 | 2015 | 66 | 0.120 |
Why?
|
Male | 15 | 2024 | 360358 | 0.120 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2016 | 239 | 0.120 |
Why?
|
Middle Aged | 12 | 2024 | 220584 | 0.120 |
Why?
|
Medical Record Linkage | 1 | 2016 | 286 | 0.120 |
Why?
|
Prevalence | 2 | 2024 | 15689 | 0.120 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2019 | 1033 | 0.120 |
Why?
|
Treatment Failure | 1 | 2021 | 2635 | 0.120 |
Why?
|
Genetic Variation | 2 | 2020 | 6561 | 0.120 |
Why?
|
Adult | 11 | 2024 | 220969 | 0.110 |
Why?
|
Ciprofloxacin | 1 | 2015 | 312 | 0.110 |
Why?
|
Qualitative Research | 1 | 2023 | 3016 | 0.110 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2022 | 3634 | 0.110 |
Why?
|
Bayes Theorem | 1 | 2021 | 2326 | 0.100 |
Why?
|
Gene Expression Profiling | 2 | 2024 | 9417 | 0.100 |
Why?
|
Recurrence | 2 | 2022 | 8426 | 0.100 |
Why?
|
Environmental Monitoring | 1 | 2019 | 1460 | 0.100 |
Why?
|
Bacteria | 2 | 2023 | 2192 | 0.100 |
Why?
|
Cross-Sectional Studies | 2 | 2023 | 26049 | 0.100 |
Why?
|
Regression Analysis | 1 | 2021 | 6338 | 0.090 |
Why?
|
Immunity, Cellular | 1 | 2017 | 1550 | 0.090 |
Why?
|
Young Adult | 4 | 2024 | 59179 | 0.090 |
Why?
|
Treatment Outcome | 6 | 2024 | 64568 | 0.090 |
Why?
|
Manometry | 1 | 2013 | 454 | 0.090 |
Why?
|
DNA Mutational Analysis | 1 | 2019 | 4110 | 0.090 |
Why?
|
Diagnostic Tests, Routine | 1 | 2016 | 786 | 0.090 |
Why?
|
Aged | 9 | 2024 | 169042 | 0.090 |
Why?
|
Multivariate Analysis | 2 | 2021 | 12043 | 0.080 |
Why?
|
Mycolic Acids | 1 | 2009 | 54 | 0.080 |
Why?
|
Adolescent | 4 | 2024 | 88234 | 0.080 |
Why?
|
Macrophages | 1 | 2024 | 5758 | 0.080 |
Why?
|
Insurance, Health | 1 | 2021 | 2495 | 0.080 |
Why?
|
Intraoperative Complications | 1 | 2015 | 1161 | 0.080 |
Why?
|
Renal Replacement Therapy | 1 | 2011 | 281 | 0.080 |
Why?
|
Electromyography | 1 | 2013 | 1393 | 0.070 |
Why?
|
Promoter Regions, Genetic | 1 | 2019 | 5780 | 0.070 |
Why?
|
Cyclophosphamide | 1 | 2013 | 2218 | 0.070 |
Why?
|
Esophagus | 1 | 2013 | 1031 | 0.070 |
Why?
|
Alleles | 2 | 2020 | 6861 | 0.070 |
Why?
|
Child | 4 | 2024 | 80079 | 0.070 |
Why?
|
Aged, 80 and over | 3 | 2022 | 58894 | 0.070 |
Why?
|
Phenotype | 5 | 2024 | 16571 | 0.070 |
Why?
|
United States | 4 | 2024 | 72272 | 0.070 |
Why?
|
Delivery of Health Care | 1 | 2023 | 5332 | 0.060 |
Why?
|
Dyspnea | 1 | 2013 | 1347 | 0.060 |
Why?
|
Veterans Disability Claims | 1 | 2024 | 24 | 0.060 |
Why?
|
Acute Kidney Injury | 2 | 2021 | 1924 | 0.060 |
Why?
|
False Positive Reactions | 1 | 2006 | 957 | 0.060 |
Why?
|
Proteomics | 1 | 2018 | 3836 | 0.060 |
Why?
|
DNA Repair | 1 | 2013 | 2043 | 0.060 |
Why?
|
Critical Care | 2 | 2021 | 2690 | 0.060 |
Why?
|
Surgical Procedures, Operative | 1 | 2015 | 1924 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2022 | 5835 | 0.060 |
Why?
|
Vietnam | 1 | 2024 | 406 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2015 | 10754 | 0.050 |
Why?
|
Prognosis | 2 | 2019 | 29600 | 0.050 |
Why?
|
Spirometry | 1 | 2024 | 928 | 0.050 |
Why?
|
Locus Control Region | 1 | 2020 | 21 | 0.050 |
Why?
|
Risk Factors | 3 | 2023 | 74115 | 0.040 |
Why?
|
Financing, Government | 1 | 2024 | 472 | 0.040 |
Why?
|
Prone Position | 1 | 2021 | 196 | 0.040 |
Why?
|
Neuromuscular Blockade | 1 | 2021 | 147 | 0.040 |
Why?
|
Pressure Ulcer | 1 | 2021 | 157 | 0.040 |
Why?
|
Creatine Kinase | 1 | 2021 | 685 | 0.040 |
Why?
|
Electronic Health Records | 1 | 2016 | 4803 | 0.040 |
Why?
|
Shock | 1 | 2021 | 314 | 0.040 |
Why?
|
South Africa | 1 | 2024 | 1836 | 0.040 |
Why?
|
Pyrazinamide | 1 | 2018 | 60 | 0.040 |
Why?
|
Pneumonia, Bacterial | 1 | 2021 | 315 | 0.040 |
Why?
|
Child, Preschool | 1 | 2021 | 42188 | 0.040 |
Why?
|
Decision Support Techniques | 1 | 2008 | 1998 | 0.040 |
Why?
|
Critical Illness | 2 | 2021 | 2709 | 0.040 |
Why?
|
Boston | 2 | 2021 | 9313 | 0.040 |
Why?
|
Geography | 1 | 2020 | 652 | 0.040 |
Why?
|
Gene Frequency | 1 | 2024 | 3601 | 0.040 |
Why?
|
Molecular Epidemiology | 1 | 2019 | 469 | 0.040 |
Why?
|
Opportunistic Infections | 1 | 2020 | 376 | 0.040 |
Why?
|
Hydroxychloroquine | 1 | 2021 | 426 | 0.030 |
Why?
|
Disability Evaluation | 1 | 2024 | 1835 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2024 | 1723 | 0.030 |
Why?
|
Disease Progression | 1 | 2013 | 13495 | 0.030 |
Why?
|
Drug Resistance | 1 | 2022 | 1594 | 0.030 |
Why?
|
Steroids | 1 | 2021 | 929 | 0.030 |
Why?
|
Occupational Diseases | 1 | 2024 | 1490 | 0.030 |
Why?
|
World Health Organization | 1 | 2022 | 1321 | 0.030 |
Why?
|
Oxidoreductases | 1 | 2018 | 412 | 0.030 |
Why?
|
Lung Transplantation | 1 | 2024 | 1310 | 0.030 |
Why?
|
Thromboembolism | 1 | 2021 | 991 | 0.030 |
Why?
|
Gonorrhea | 1 | 2018 | 346 | 0.030 |
Why?
|
Disabled Persons | 1 | 2024 | 1226 | 0.030 |
Why?
|
Antimalarials | 1 | 2021 | 907 | 0.030 |
Why?
|
Models, Molecular | 1 | 2024 | 5433 | 0.030 |
Why?
|
Lung Diseases | 1 | 2024 | 1909 | 0.030 |
Why?
|
Access to Information | 1 | 2016 | 316 | 0.030 |
Why?
|
Propensity Score | 1 | 2020 | 1911 | 0.030 |
Why?
|
Emergency Treatment | 1 | 2015 | 495 | 0.020 |
Why?
|
Antibodies, Bacterial | 1 | 2018 | 1463 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2023 | 2630 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2006 | 12966 | 0.020 |
Why?
|
Disease Outbreaks | 1 | 2020 | 1748 | 0.020 |
Why?
|
Cross Infection | 1 | 2020 | 1422 | 0.020 |
Why?
|
Protein Conformation | 1 | 2018 | 3965 | 0.020 |
Why?
|
Genetic Markers | 1 | 2017 | 2601 | 0.020 |
Why?
|
Information Storage and Retrieval | 1 | 2016 | 819 | 0.020 |
Why?
|
Epidemics | 1 | 2016 | 512 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 6474 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2015 | 2849 | 0.020 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2021 | 1462 | 0.020 |
Why?
|
Hospital Costs | 1 | 2015 | 947 | 0.020 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2024 | 3204 | 0.020 |
Why?
|
Length of Stay | 1 | 2021 | 6418 | 0.020 |
Why?
|
Forecasting | 1 | 2016 | 2924 | 0.020 |
Why?
|
Survival Rate | 1 | 2021 | 12719 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2016 | 15251 | 0.020 |
Why?
|
Comorbidity | 1 | 2021 | 10505 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2018 | 13441 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2013 | 36402 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2018 | 5110 | 0.020 |
Why?
|
Metabolic Networks and Pathways | 1 | 2009 | 789 | 0.020 |
Why?
|
Age Factors | 1 | 2021 | 18381 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8645 | 0.010 |
Why?
|
Time Factors | 2 | 2016 | 39913 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7389 | 0.010 |
Why?
|
Fatty Acids | 1 | 2009 | 1808 | 0.010 |
Why?
|
Logistic Models | 1 | 2015 | 13245 | 0.010 |
Why?
|
Risk Assessment | 2 | 2015 | 23972 | 0.010 |
Why?
|
Databases, Factual | 1 | 2015 | 7960 | 0.010 |
Why?
|
Cohort Studies | 1 | 2023 | 41457 | 0.010 |
Why?
|
Survival Analysis | 1 | 2011 | 10073 | 0.010 |
Why?
|
Algorithms | 2 | 2009 | 14018 | 0.010 |
Why?
|
Prospective Studies | 1 | 2021 | 54360 | 0.010 |
Why?
|
Internet | 1 | 2008 | 3090 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2011 | 10199 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2015 | 15612 | 0.010 |
Why?
|
Models, Biological | 1 | 2009 | 9461 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2009 | 11874 | 0.010 |
Why?
|
Animals | 1 | 2013 | 168201 | 0.000 |
Why?
|